CRCM  Vol.4 No.5 , May 2015
Propranolol-Induced Epistaxis in a Woman with Multiple Obstetric Complications: Case Report
ABSTRACT
Epistaxis is a common complaint which is rarely life-threatening, as most cases are self-limited and as such unreported. However, it may be a significant cause for concern if it becomes recurrent. Although a number of medications including topical antihistamines and non-steroidal anti-inflammatory drugs are known aetiological factors for epistaxis due to their antiplatelet effects, beta blockers are not being widely reported as a possible cause. This report presents the case of a 34-year-old G2P0+1, who was diagnosed with hyperthyroidism in pregnancy and subsequently reported epistaxis twice at different occasion and different hospital settings when propranolol was introduced for her treatment, with resolution of epistaxis after withdrawal of propranolol. The report aims to highlight and sensitize physicians to the possible risk of bleeding in patients placed on beta blockers especially propranolol for a wide range of medical condition due to its thrombocytopathic effect.

Cite this paper
Otegbayo, J. , Imaralu, J. and Osibowale, B. (2015) Propranolol-Induced Epistaxis in a Woman with Multiple Obstetric Complications: Case Report. Case Reports in Clinical Medicine, 4, 193-196. doi: 10.4236/crcm.2015.45039.
References
[1]   Rajput, A.H. and Rajput, A. (2014) Medical Treatment of Essential Tremor. Journal of Central Nervous System Disease, 6, 29-39.
http://dx.doi.org/10.4137/JCNSD.S13570

[2]   Pringsheim, T., Davenport, W., Mackie, G., Worthington, I., Aubé, M., Christie, S.N., Gladstone, J., Becker, W.J. and Canadian Headache Society Prophylactic Guidelines Development Group (2012) Canadian Headache Society Guideline for Migraine Prophylaxis. Canadian Journal of Neurological Sciences, 39, S1-S59.

[3]   Akbar, S. and Alorainy, M.S. (2014) The Current Status of Beta Blockers’ Use in the Management of Hypertension. Saudi Medical Journal, 35, 1307-1317.

[4]   Ohrstrom, A., Kattstrom, O., Polland, W., Mortensen, J. and Stenstrom, B. (1984) Oral and Topical Adrenergic Beta-Receptor Blockers in Glaucoma Treatment. A Multicenter Study. Acta Ophthalmologica, 62, 681-695.
http://dx.doi.org/10.1111/j.1755-3768.1984.tb05795.x

[5]   Stephen, S.A. (1966) Unwanted Effects of Propranolol. The American Journal of Cardiology, 18, 463-472.
http://dx.doi.org/10.1016/0002-9149(66)90071-3

[6]   British Medical Association (2002) British National Formulary, Royal Pharmaceutical Society of Great Britain. 77-78.

[7]   Salako, B.L., Odukogbe, A.T., Olayemi, O., Adedapo, K.S., Aimakhu, C.O., Alu, F.E. and Ola, B. (2003) Serum Albumin, Creatinine, Uric Acid and Hypertensive Disorders of Pregnancy. East African Medical Journal, 80, 424-428.

[8]   Hershman, J.M. (1992) Role of Human Chorionic Gonadotropin as a Thyroid Stimulator. The Journal of Clinical Endocrinology and Metabolism, 74, 258-259.

[9]   Omigbodun, A.O. (2004) Recent Trends in the Management of Anaemia in Pregnancy. Tropical Journal of Obstetrics and Gynaecology, 21, 1-3.

[10]   Weksler, B.B., Gillick, M. and Pink, J. (1977) Effect of Propranolol on Platelet Function. Blood, 49, 185-196.

[11]   Dash, D. and Rao, K. (1995) Effect of Propranolol on Platelet Signal Transduction. Biochemical Journal, 309, 99-104.

[12]   Punda, A., Polic, S., Rumboldt, Z., Bagatin, J., Markovic, V. and Lukin, A. (2005) Effects of Atenolol and Propranolol on Platelet Aggregation in Moderate Essential Hypertension: Randomized Crossover Trial. Croatian Medical Journal, 46, 219-224.

 
 
Top